Please ensure Javascript is enabled for purposes of website accessibility

Meet the 2 Newest Investments in Cystic Fibrosis

By Maxx Chatsko - Sep 29, 2013 at 12:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors can now invest in two new companies eyeing the orphan disease. Are they worth it?

Individuals with cystic fibrosis, or CF, have relatively few treatment options available to them. Approved medicines largely focus on reducing inflammation and keeping infections at bay -- treating symptoms of the disease, not the cause. For instance, Pulmozyme from Roche (RHHBY -2.50%) was the first approved treatment for CF. The drug is an enzyme that breaks down mucus in the lungs, which improves breathing and the body's ability to clear such mucus. It fetched $305 million in sales for Roche in the first half of this year, but it is approved for multiple indications worldwide and is hardly the best the industry has to offer. 

Promising new research in the genetics of CF is about to change that. Kalydeco from Vertex Pharmaceuticals (VRTX -1.22%) is approved to treat patients with a certain mutation, G551D, in the gene encoding the CFTR protein, which controls fluid flow in and out of cells. The drug has greatly improved the lives of cystic fibrosis patients with the mutation -- about 4% of all patients -- and generated sales of $160 million in the first half of 2013. Not very promising, but consider that pipeline candidates currently being evaluated in clinical trials that treat another genetic mutation, F508del, could allow Vertex to treat 90% of the cystic fibrosis population and generate peak sales of $1.7 billion by 2018.  

The prospects have spurred others to dig into genetic data to unveil targets for treating cystic fibrosis more effectively. Who are the latest entrants? Are they investment-worthy on the backs of CF treatments alone? Fool contributor Maxx Chatsko explains in the following video.

Fool contributor Maxx Chatskohas no position in any stocks mentioned. Check out his personal portfolio or his CAPS page, or follow him on Twitter, @BlacknGoldFool, to keep up with his writing on biopharmaceuticals, industrial biotech, and the bioeconomy.

The Motley Fool recommends Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$292.16 (-1.22%) $-3.61
AbbVie Inc. Stock Quote
AbbVie Inc.
$142.08 (0.81%) $1.14
PTC Therapeutics, Inc. Stock Quote
PTC Therapeutics, Inc.
$52.01 (-3.16%) $-1.70
Roche Holding AG Stock Quote
Roche Holding AG
$41.04 (-2.50%) $-1.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.